AN2 Therapeutics Inc. has synthesized boron heterocycle-containing compounds acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors. They are designed for potential use in the treatment of cancer, hypophosphatasia, infections, metabolic, autoimmune and autoinflammatory diseases.
Researchers from Sungkyunkwan University and Txinno Bioscience Inc. recently presented their work where they aimed to design, synthesize and evaluate ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitors containing a benzotriazole core and a sulfonimidamide Zn binder.
Arc Research Institute and Stanford University have disclosed ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) and/or ENPP3 inhibitors reported to be useful for the treatment of cancer.
The overexpression of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) is tied to poor prognosis in several cancer types, including osteosarcoma and Ewing sarcoma, and is therefore a potential therapeutic target in these cancers. In this regard, Avammune Therapeutics Inc. is developing an ENPP1 inhibitor – AVA-NP-695.
The FDA has cleared AD-NP1, a drug developed by University of California, Los Angeles (UCLA) for heart tissue regeneration, to enter clinical trials. The monoclonal antibody blocks the production of ENPP1 protein, which was found to interfere with healing after a heart attack.
Rallybio Corp. has received an equity milestone payment of $12.5 million from Recursion Pharmaceuticals Inc. triggered by the initiation of additional preclinical studies for REV-102, an investigational oral ENPP1 inhibitor.
Korea Institute of Science and Technology has identified ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer.
Researchers at Cimplrx Co. Ltd. and Samjin Pharmaceutical Co. Ltd. have identified ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer, hypophosphatemia, osteoarthritis, cystic fibrosis, type 2 diabetes, Alzheimer’s disease, and viral and bacterial infections.
ENPP1 contributes to establishing an immunosuppressive tumor microenvironment by blocking the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling, which is critical in antitumor immunity. The inhibition of ENPP1 is an emerging strategy under exploration for cancer immunotherapy.
Haihe Biopharma Co. Ltd. has published work on the discovery of novel ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) inhibitors being developed for the treatment of cancer.
